Therefore, CNA of the IFN gene cluster can be suggested as a useful biomarker to predict the prognosis of patients (e.g., liver and renal cancers) and also as a potential companion diagnostic test to prescribe IFN α/β therapy and predict the outcome of immunotherapy for clinical use. Here, IFNA1 is linked to renal carcinoma.